CABA

0.93617.32%
SA

Steven A. Nichtberger

Co-Founder, Chairman, CEO & President

Dr. Steven A. Nichtberger, M.D., serves as managing partner of GBF Advisors, LLC. Dr. Nichtberger is an adjunct professor at The Wharton School at the University of Pennsylvania. He is Co-Founder of Cabaletta Bio, Inc. and has been its Chief Executive Officer, President and Chairman since 2017. He is Director of ControlRad Systems, Inc. and served as Chairman. He serves as Chief Executive Officer of IntelliRad Control, Inc. Dr. Nichtberger serves as an Executive Director at IntelliRad Control, Inc. He serves as a Venture Advisor at Israel Biotech Fund. Dr. Nichtberger is an Adjunct Professor at Wharton School. He served as the Chief Executive Officer at ControlRad Systems until July 2015. Dr. Nichtberger has a distinguished career in the biopharmaceutical industry including his current role as a Founder and Chief Executive of innovative, emerging life sciences companies. He served as the Chief Executive Officer and President of Tengion Inc. from May 2004 to June 30, 2011. Dr. Nichtberger served as a Vice President at Merck & Co., Inc., where he was responsible for leadership of global marketing and new product planning and was a core participant in many corporate licensing, divestiture and product acquisition deals. Dr. Nichtberger was also former Head of Marketing at Merck. He held a number of senior management positions at Merck & Co., Inc. including: leadership of the global marketing organization with responsibility for developing and setting strategy for all Merck & Co., Inc. brands globally through the efforts of 350 employees and a 200 million budget; operational leadership of the Merck & Co., Inc. hypertension franchise comprised of six brands, with full P&L responsibility for the franchise; and leadership of the New Products Group with responsibility for development of strategy for all pipeline products at Merck & Co., Inc. He also had experience and interaction with the Research and Manufacturing Divisions during his career at Merck & Co., Inc. Dr. Nichtberger was the lead marketing executive on many corporate licensing, divestiture and product acquisition teams at Merck & Co., Inc., including the core team that established the Merck & Co., Inc.-Schering-Plough partnerships around Zetia and Vytorin. He founded, developed and managed a profitable privately held company based upon a patented paperless coupon system. Dr. Nichtberger is a successful founding Entrepreneur and Board Certified Internist and Cardiologist at Mount Sinai Medical Center in New York. He holds healthcare and industry experience focused on developing and commercializing breakthrough medical advances. Dr. Nichtberger served as Chair of The Pennsylvania Biotechnology Association and serves as its Director. He served as Member of Board of Trustees at Main Line Health, Inc. He serves as a Director of BioAdvance. He has been a Director and Member of Health Section Governing Board at Biotechnology Industry Organization since July 2011. He served as a Director of Tengion Inc. since May 2004 until June 30, 2011. He received a B.A. in Biology from University of Pennsylvania in 1983 and B.S. in Economics and Entrepreneurial Management from Wharton School. Dr. Nichtberger holds an M.D. from School of Medicine and Biosciences, State University of New York at Buffalo in 1989.

Positions